D. Caracciolo

发表

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma

Mario Cannataro, Pietro Hiram Guzzi, Gareth J. Morgan, 2015, Oncotarget.

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches

P. Tassone, P. Tagliaferri, D. Caracciolo, 2018, Journal of Hematology & Oncology.

In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells

P. Tassone, P. Tagliaferri, M. D. Di Martino, 2014, PloS one.

Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes

M. Cannataro, P. Tassone, P. Tagliaferri, 2022, Cells.

High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity

A. Pileri, M. Ladetto, D. Caracciolo, 2001, Leukemia.

Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis

P. Tagliaferri, V. Barbieri, D. Caracciolo, 2022, ESMO open.

Error‐prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment

P. Tassone, P. Tagliaferri, M. D. Di Martino, 2020, International journal of cancer.

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis

P. Tassone, P. Tagliaferri, M. Caraglia, 2020, Cells.

Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.

D. Caracciolo, U. Ricardi, G. Bisi, 2013, International journal of radiation oncology, biology, physics.

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma

M. Boccadoro, S. Ferrero, M. Ladetto, 2013, Annals of Hematology.

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

M. Boccadoro, D. Caracciolo, F. Patriarca, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting.

A. Pileri, C. Voena, M. Ladetto, 1997, Blood.

Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation.

D. Caracciolo, U. Ricardi, G. Bisi, 2016, International journal of radiation oncology, biology, physics.

Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status

M. Boccadoro, M. Ladetto, C. Carlo-Stella, 2010, Bone Marrow Transplantation.

Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir.

M. Boccadoro, M. Ladetto, C. Carlo-Stella, 2007, Experimental hematology.

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.

M. Ladetto, M. Di Nicola, D. Caracciolo, 2016, International journal of radiation oncology, biology, physics.

Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft

A. Pileri, M. Ladetto, D. Caracciolo, 2000, Leukemia.

The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma

P. Tassone, P. Tagliaferri, M. Arbitrio, 2022, International journal of molecular sciences.

Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.

M. Boccadoro, A. Pileri, D. Caracciolo, 1993, Bone marrow transplantation.

Differential activity of recombinant colony‐stimulating factors in supporting proliferation of human peripheral blood and bone marrow myeloid progenitors in culture

D. Caracciolo, G. Rovera, S. Clark, 1989, British journal of haematology.

Synergistic and antagonistic effects of recombinant human interleukin (IL) 3, IL-1 alpha, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines.

D. Caracciolo, D. Santoli, S. Clark, 1987, Journal of immunology.

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice

P. Tassone, P. Tagliaferri, M. Arbitrio, 2020, Clinical and translational science.

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

M. Boccadoro, A. Pileri, M. Ladetto, 2001, Leukemia.

Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions

A. Pileri, M. Ladetto, D. Caracciolo, 1999, Leukemia.

Hemopoietic Progenitor Cell Mobilization and Harvest Following an Intensive Chemotherapy Debulking in Indolent Lymphoma Patients

A. Pileri, D. Caracciolo, P. Corradini, 1999, Stem cells.

Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high‐dose chemotherapy courses

A. Palumbo, M. Boccadoro, A. Pileri, 1997, British journal of haematology.

Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome

A. Pileri, D. Caracciolo, P. Corradini, 1997, British journal of haematology.

High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.

M. Boccadoro, G. Bonadonna, D. Caracciolo, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Usefulness and Optimal Harvesting of Peripheral Blood Stem Cells Mobilized by High Dose Cyclophosphamide and Recombinant Human GM-CSF

D. Caracciolo, S. Siena, F. Ravagnani, 1993 .

Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSF.

D. Caracciolo, S. Clark, G. Rovera, 1989, Blood.

High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization

A. Pileri, A. Gallamini, D. Caracciolo, 2002, Bone Marrow Transplantation.

Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas.

A. Pileri, D. Caracciolo, P. Corradini, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemia.

D. Caracciolo, C. Tarella, D. Bono, 2005, Contributions to nephrology.

Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: Non-Hodgkin's lymphoma

A. Pileri, D. Caracciolo, V. Tassi, 2002, Annals of Hematology.

High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments

M. Boccadoro, A. Pileri, M. Ladetto, 2001, Annals of Hematology.

Use of peripheral blood stem cells to accelerate hemopoietic recovery following autologous bone marrow transplantation.

F. Locatelli, A. Urgesi, D. Caracciolo, 1990, Haematologica.

Immunological separation of two CFU-GM subsets showing different responsiveness to T-cell derived growth factors.

D. Caracciolo, G. Bellone, D. Ferrero, 1988, Journal of clinical & laboratory immunology.

A single step density gradient separation for large scale enrichment of mobilized peripheral blood progenitor cells collected for autotransplantation

A. Pileri, D. Caracciolo, P. Omedé, 1998, Bone Marrow Transplantation.

Establishment from an adult leukemic patient of two novel precursor B cell lines with different growth modality.

D. Caracciolo, L. Lanfrancone, D. Ferrero, 1990, Leukemia research.

Establishment and characterization of an undifferentiated human T leukemia cell line which requires granulocyte-macrophage colony stimulatory factor for growth.

D. Tweardy, B. Lange, D. Caracciolo, 1987, Journal of immunology.

Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma

A. Palumbo, M. Boccadoro, A. Pileri, 1998, Bone Marrow Transplantation.

Protooncogenes in the Regulation of Normal Hematopoiesis. An Antisense Approach a

B. Calabretta, T. Skorski, C. Szczylik, 1992, Annals of the New York Academy of Sciences.

Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.

B. Calabretta, M. Ratajczak, A. Gewirtz, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival

A. Rossi, D. Caracciolo, G. Gritti, 2014, PloS one.

Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin

P. Tassone, P. Tagliaferri, F. Vasile, 2022, Journal of Translational Medicine.

Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis

P. Tassone, P. Tagliaferri, M. Caraglia, 2021, Life.

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221

P. Tassone, P. Tagliaferri, C. Erratico, 2019, Cancers.

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

P. Tassone, P. Tagliaferri, A. Giordano, 2021, Journal for ImmunoTherapy of Cancer.

Recombinant human macrophage colony-stimulating factor (M-CSF) requires subliminal concentrations of granulocyte/macrophage (GM)-CSF for optimal stimulation of human macrophage colony formation in vitro

B. Lange, D. Caracciolo, S. Clark, 1987, The Journal of experimental medicine.

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells

P. Tassone, P. Tagliaferri, S. Sestito, 2022, Cancers.

Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia.

M. Boccadoro, D. Caracciolo, A. Busca, 2016, Clinical lymphoma, myeloma & leukemia.

Patients with high‐risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting

M. Boccadoro, A. Pileri, M. Dell'aquila, 2003, Cancer.

The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives

P. Tassone, P. Tagliaferri, D. Caracciolo, 2023, Experimental Hematology & Oncology.

Lineage-specific requirement of c-abl function in normal hematopoiesis.

B Calabretta, C. Peschle, B. Calabretta, 1989, Science.

C. Peschle, B. Calabretta, D. Caracciolo, 1990, The Journal of clinical investigation.

miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy

P. Tassone, P. Tagliaferri, M. Arbitrio, 2021, Cancers.

From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology

Pietro Hiram Guzzi, Maria Eugenia Gallo Cantafio, Katia Grillone, 2018, High-throughput.

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity

N. Munshi, P. Tassone, P. Tagliaferri, 2018, Leukemia.

Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel

P. Tassone, P. Tagliaferri, D. Caracciolo, 2021, Cancers.

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity

P. Tassone, P. Tagliaferri, A. Giordano, 2014, Oncotarget.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

N. Munshi, P. Tassone, P. Tagliaferri, 2018, Blood.

From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.

P. Tassone, P. Tagliaferri, D. Caracciolo, 2013, Current drug targets.

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case‐Control Study

Mario Cannataro, Giuseppe Agapito, Mariamena Arbitrio, 2019, Clinical pharmacology and therapeutics.

Alternative non-homologous end joining repair: a master regulator of genomic instability in cancer

P. Tassone, P. Tagliaferri, D. Caracciolo, 2019, Precision Cancer Medicine.

Integration of DNA Microarray with Clinical and Genomic Data.

P. Tassone, P. Tagliaferri, M. Arbitrio, 2021, Methods in molecular biology.

Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines

P. Nowell, B. Emanuel, B. Lange, 1987 .

Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines.

B. Emanuel, B. Lange, C. Griffin, 1987, Blood.

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2020, Haematologica.

The potential role of miRNAs in multiple myeloma therapy

P. Tassone, P. Tagliaferri, D. Caracciolo, 2018, Expert review of hematology.

Tools in Pharmacogenomics Biomarker Identification for Cancer Patients.

P. Tagliaferri, M. Arbitrio, D. Caracciolo, 2021, Methods in molecular biology.

The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy

A. Rossi, M. Ladetto, D. Caracciolo, 2013, American journal of hematology.

Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report.

D. Caracciolo, C. Santoro, M. Gentile, 2021, Blood Coagulation and Fibrinolysis.

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

N. Munshi, C. Mignogna, P. Tassone, 2017, Leukemia.

Granulocyte-macrophage colony-stimulating factor requires interaction with accessory cells or granulocyte-colony stimulating factor for full stimulation of human myeloid progenitors.

A. Pileri, D. Caracciolo, G. Bellone, 1989, Blood.

Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.

A. Rossi, M. Di Nicola, A. Gallamini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs

A. Pileri, F. Locatelli, D. Caracciolo, 1998, Bone Marrow Transplantation.

Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high‐dose chemotherapy + G‐CSF

A. Pileri, D. Caracciolo, A. Gianni, 1995, British journal of haematology.

miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

P. Tassone, P. Tagliaferri, M. Gaspari, 2020, Leukemia.

Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line.

D. Tweardy, D. Caracciolo, M. Valtieri, 1987, Journal of immunology.

Survival in HIV‐infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study

P. Zinzani, P. Zinzani, D. Caracciolo, 2018, HIV medicine.

Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF

M. Dell'aquila, M. Ladetto, C. Carlo-Stella, 2005, Leukemia.

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial.

P. Arcidiacono, D. Caracciolo, A. Ferreri, 2012, Blood.

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

M. Boccadoro, M. Ladetto, A. Gallamini, 2007, Leukemia.

Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft

A. Pileri, C. Magnani, D. Caracciolo, 2000, Bone Marrow Transplantation.

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

P. Tassone, P. Tagliaferri, V. Barbieri, 2019, Journal of Hematology & Oncology.

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas

P. Tassone, P. Tagliaferri, M. Arbitrio, 2023, Cancers.

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

P. Tassone, P. Tagliaferri, M. Caraglia, 2020, Journal for immunotherapy of cancer.

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts

P. Tassone, P. Tagliaferri, A. Giordano, 2015, Oncotarget.

Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data

Mario Cannataro, Giuseppe Agapito, Mariamena Arbitrio, 2021, J. Comput. Sci..

Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2–3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis

M. Boccadoro, M. Ladetto, A. Gallamini, 2004 .

A First-in-Class Pronectin™-based Bispecific T Cell Engager Anti-AXL x CD3 for the Treatment of Epithelial Ovarian Cancer

G. Nisticó, Tatjana, D. Caracciolo, 2022 .

Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization.

A. Pileri, D. Caracciolo, S. Siena, 1995, Bone marrow transplantation.

Role of Na+/H+ exchange in the granulocyte‐macrophage colony‐stimulating factor‐dependent growth of a leukemic cell line

D. Caracciolo, F. Bussolino, F. Turrini, 1990, Journal of cellular physiology.

Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

R. Foà, D. Rossi, G. Gaidano, 2021, American journal of hematology.

Mir-221/222 are promising targets for innovative anticancer therapy

Marco Rossi, Pierosandro Tagliaferri, Pierfrancesco Tassone, 2016, Expert opinion on therapeutic targets.

TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma

P. Tassone, P. Tagliaferri, M. Arbitrio, 2023, Journal of Experimental & Clinical Cancer Research.

miR-22 suppresses DNA ligase III addiction in multiple myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2018, Leukemia.

miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review

P. Tassone, P. Tagliaferri, M. Arbitrio, 2022, Molecular therapy. Nucleic acids.

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2019, Cancers.

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori-Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

P. Arcidiacono, D. Caracciolo, A. Ferreri, 2011 .

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer

P. Tassone, P. Tagliaferri, D. Caracciolo, 2023, Journal of Translational Medicine.

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2021, Cancers.

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2017, Oncotarget.

COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment

D. Caracciolo, G. Stroffolini, A. Calcagno, 2021, HemaSphere.

Selection and characterization of early hematopoietic progenitors using an anti-CD71/S06 immunotoxin.

A. Pileri, D. Caracciolo, A. Gianni, 1994, Experimental hematology.

High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma.

F. Locatelli, M. Aglietta, D. Caracciolo, 1993, Bone marrow transplantation.

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats

P. Tassone, P. Tagliaferri, M. Arbitrio, 2020, Molecular therapy. Nucleic acids.

Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

P. Tassone, P. Tagliaferri, D. Caracciolo, 2017, Current cancer drug targets.

A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.

P. Tassone, P. Tagliaferri, D. Caracciolo, 2019, European journal of medicinal chemistry.

Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemia.

D. Caracciolo, C. Tarella, D. Bono, 2005, Contributions to nephrology.

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

P. Tassone, P. Tagliaferri, V. Barbieri, 2023, Journal of Hematology & Oncology.

MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers

Daniele Caracciolo, Marzia Settino, Mario Cannataro, 2020, ICCS.

A Prospective, Observational Study Evaluating Early Subclinical Cardiotoxicity with Global Longitudinal Strain Imaging in Lymphoma Patients Treated with Chemotherapy +/- Mediastinal Radiation Therapy: The CARDIOCARE Project

V. D. Luca, D. Caracciolo, G. Priolo, 2018, International Journal of Radiation Oncology*Biology*Physics.

The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation.

M. Boccadoro, M. Ladetto, D. Caracciolo, 2007 .

Tumor‐derived Growth Factors That Support Proliferation and Differentiation of Normal and Leukemic Hemopoietic Cells

D. Tweardy, D. Caracciolo, M. Valtieri, 1987, Annals of the New York Academy of Sciences.

A Case of Immune Thrombocytopenia After COVID-19 Vaccination: Coincidental or Causal Effect? Running Title: ITP After COVID-19 Vaccination

D. Caracciolo, M. Gentile, E. Vigna, 2021 .

The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy

A. Rossi, M. Ladetto, D. Caracciolo, 2013, American journal of hematology.